Ghent University Academic Bibliography

Journal Article
A1
open access

Targeting replication stress in neuroblastoma by exploiting the synergistic potential of second generation RRM2 and CHK1 inhibitors

Iris Nelen (UGent) , Soetkin Leys (UGent) , Sarah-Lee Bekaert (UGent) , Fanny De Vloed (UGent) , Fien Martens (UGent) , Ellen Sanders (UGent) , Angeline Praveena Enton Raj, Annika Jeschke, Shunya Ohmura, Thomas G P Grünewald, et al.

(2026) CELL DEATH & DISEASE. 17(1).

Add to list

PhD Thesis

Human pluripotent stem cell modeling, from normal development to neuroblastoma

Stéphane Van Haver

(2024)

Add to list

Journal Article
A1
open access

Targeted AURKA degradation : towards new therapeutic agents for neuroblastoma

Muhammad Rishfi (UGent) , Simon Krols (UGent) , Fien Martens (UGent) , Sarah-Lee Bekaert (UGent) , Ellen Sanders (UGent) , Aline Eggermont (UGent) , Fanny De Vloed (UGent) , Joshua Robert Goulding (UGent) , Martijn Risseeuw (UGent) , Jan Molenaar, et al.

(2023) EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY. 247.

Add to list

Journal Article
A1
open access

Mitotic dysregulation at tumor initiation creates a therapeutic vulnerability to combination anti-mitotic and pro-apoptotic agents for MYCN-driven neuroblastoma

Lei Zhai, Anushree Balachandran, Rebecca Larkin, Janith A. Seneviratne, Sylvia A. Chung, Amit Lalwani, Shoma Tsubota, Dominik Beck, Kenji Kadomatsu, Anneleen Beckers (UGent) , et al.

(2023) INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 24(21).

Add to list

Journal Article
A1
open access

The feasibility of using liquid biopsies as a complementary assay for copy number aberration profiling in routinely collected paediatric cancer patient samples

Ruben Van Paemel (UGent) , Charlotte Vandeputte, Lennart Raman, Jolien Van Thorre, Leen Willems (UGent) , Jo Van Dorpe (UGent) , Malaïka Van der Linden (UGent) , Jilke De Wilde (UGent) , Andries De Koker (UGent) , Björn Menten (UGent) , et al.

(2022) EUROPEAN JOURNAL OF CANCER. 160. p.12-23

Add to list

Journal Article
A1
open access

From DNA copy number gains and tumor dependencies to novel therapeutic targets for high-risk neuroblastoma

Bieke Decaesteker (UGent) , Kaat Durinck (UGent) , Nadine Van Roy (UGent) , Bram De Wilde (UGent) , Christophe Van Neste (UGent) , Stéphane Van Haver, Stephen Roberts, Katleen De Preter (UGent) , Vanessa Vermeirssen (UGent) and Franki Speleman (UGent)

(2021) JOURNAL OF PERSONALIZED MEDICINE. 11(12).

Add to list

Journal Article
A1
open access

ALK ligand ALKAL2 potentiates MYCN‐driven neuroblastoma in the absence of ALK mutation

Marcus Borenäs, Ganesh Umapathy, Wei‐Yun Lai, Dan E Lind, Barbara Witek, Jikui Guan, Patricia Mendoza‐Garcia, Tafheem Masudi, Arne Claeys (UGent) , Tzu‐Po Chuang, et al.

(2021) EMBO JOURNAL. 40(3).

Add to list

Journal Article
A1
open access

A G316A polymorphism in the ornithine decarboxylase gene promoter modulates MYCN-driven childhood neuroblastoma

Laura D. Gamble, Stefania Purgato, Michelle J. Henderson, Simone Di Giacomo, Amanda J. Russell, Paolo Pigini, Jayne Murray, Emanuele Valli, Giorgio Milazzo, Federico M. Giorgi, et al.

(2021) CANCERS. 13(8).

Add to list

Journal Article
A1
open access

MEIS2 is an adrenergic core regulatory transcription factor involved in early initiation of TH-MYCN-driven neuroblastoma formation

Jolien De Wyn, Mark W. Zimmerman, Nina Weichert-Leahey, Carolina de Carvalho Nunes, Belamy B. Cheung, Brian J. Abraham, Anneleen Beckers (UGent) , Pieter-Jan Volders (UGent) , Bieke Decaesteker (UGent) , Daniel R. Carter, et al.

(2021) CANCERS. 13(19).

Add to list

Journal Article
A1
open access

The ETS transcription factor ETV5 is a target of activated ALK in neuroblastoma contributing to increased tumour aggressiveness

Liselot Mus (UGent) , Irina Lambertz (UGent) , Shana Claeys (UGent) , Candy Kumps (UGent) , Wouter Van Loocke (UGent) , Christophe Van Neste (UGent) , Ganesh Umapathy, Marica Vaapil, Christoph Bartenhagen, Genevieve Laureys (UGent) , et al.

(2020) SCIENTIFIC REPORTS. 10.

Academic Bibliography

Targeting replication stress in neuroblastoma by exploiting the synergistic potential of second generation RRM2 and CHK1 inhibitors

Human pluripotent stem cell modeling, from normal development to neuroblastoma

Targeted AURKA degradation : towards new therapeutic agents for neuroblastoma

Mitotic dysregulation at tumor initiation creates a therapeutic vulnerability to combination anti-mitotic and pro-apoptotic agents for MYCN-driven neuroblastoma

The feasibility of using liquid biopsies as a complementary assay for copy number aberration profiling in routinely collected paediatric cancer patient samples

From DNA copy number gains and tumor dependencies to novel therapeutic targets for high-risk neuroblastoma

ALK ligand ALKAL2 potentiates MYCN‐driven neuroblastoma in the absence of ALK mutation

A G316A polymorphism in the ornithine decarboxylase gene promoter modulates MYCN-driven childhood neuroblastoma

MEIS2 is an adrenergic core regulatory transcription factor involved in early initiation of TH-MYCN-driven neuroblastoma formation

The ETS transcription factor ETV5 is a target of activated ALK in neuroblastoma contributing to increased tumour aggressiveness

Contents

Support

Contact